Immune Therapeutics, Inc.
Immune Therapeutics, Inc. (IMUN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
imun · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Immune Therapeutics, Inc. (IMUN) measures how much investors pay for each dollar of the company's trailing earnings. IMUN's current PE ratio of N/A is calculated by dividing its stock price of $0.09 by its TTM earnings per share of -$0.03.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2012 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Immune Therapeutics, Inc.You IMUN | $8M | N/A | — | -$0.03 |
 Bionomics Limited BNOEF | $9M | N/A | — | -$1898.63 |
 Carebook Technologies Inc. CRBKF | $7M | N/A | — | -$0.27 |
 Forward Pharma A/S FWPAY | $7M | N/A | — | -$77.41 |
 HealthBeacon plc HBCNF | $8M | N/A | — | -$0.78 |
 Intellipharmaceutics International Inc. IPCIF | $5M | N/A | — | -$0.09 |
 MDxHealth S.A. MXDHF | $9M | N/A | — | -$0.67 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-0.16 | — | |
2021-12-31 FY2021 | 0.40x | $7.41 | -93.3% | |
2020-12-31 FY2020 | 6.03x | $2.40 | — | |
2019-12-31 FY2019 | — | $-10.44 | — | |
2018-12-31 FY2018 | — | $-19.03 | — | |
2017-12-31 FY2017 | — | $-22.81 | — | |
2016-12-31 FY2016 | — | $-90.09 | — | |
2015-12-31 FY2015 | — | $-106.46 | — | |
2014-12-31 FY2014 | — | $-489.84 | — | |
2013-12-31 FY2013 | — | $-1853.09 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Immune Therapeutics, Inc. (IMUN) measures how much investors pay for each dollar of the company's trailing earnings. IMUN's current PE ratio of N/A is calculated by dividing its stock price of $0.09 by its TTM earnings per share of -$0.03.
Frequently asked questions
IMUN pe ratio · 6 questionsIMUN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.09 and TTM EPS of -$0.03. Data sourced from Financial Modeling Prep via IMUN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Immune Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09